StockHotTips.com Hot Stock News & Alerts!
StockHotTips.com Stock Watch!
*************************************************************
Power3 Medical Products, Inc. (OTCBB: PWRM) has announced that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro® protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept® (Donepezil HCl, Pfizer – NYSE: PFE), Exelon® (Rivastigmine, Novartis – NYSE: NVS), and Namenda® (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.
(OTCBB: PWRM) is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).
For More Information On (OTCBB: PWRM) Go To :http://www.power3medical.com.
CombiMatrix Corporation (Nasdaq:CBMX) recently announced that it has instructed its investment bankers to cease work on identification and pursuit of potential purchasers of the company or its assets. For the past several months, CombiMatrix has had discussions with parties about a sale of the company or assets of the company. The Board of Directors has determined that the company should now focus exclusively on building and growing the diagnostics services business. One component of that endeavor is the recruitment and hiring of a commercially focused executive who will replace outgoing CEO Dr. Amit Kumar.
(Nasdaq:CBMX) is a diversified biotechnology business that primarily operates in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary, CombiMatrix Diagnostics (”CMDX”). CMDX operates as a diagnostics reference laboratory that provides genetic and other diagnostics services to physicians, hospitals and clinics.
Leuchemix Inc. (”Leuchemix”), a minority owned subsidiary, is developing a series of compounds to address a number of oncology-related diseases. Leuchemix’s first compound has entered initial clinical trials in the United Kingdom.
Additional information about (Nasdaq:CBMX) is available at www.combimatrix.com
Cord Blood America, Inc. (http://www.cordblood-america.com ) (OTC Bulletin Board:CBAI.ob), said today that its co-founder and CEO, Matthew Schissler, reviewed the reasons for and significant details about its new “Afford-A-Cord” program in an interview with analyst Francis Gaskins.
The “Afford-A-Cord” program, which is being launched this month, reduces the initial cost of storing umbilical cord blood stem cells from $2075 to $495 plus medical courier service.
In the interview Mr. Schissler stated “The program is being offered as an additional payment option to our longstanding traditional payment programs”. He also stated “We are breaking new ground as we open up this service to an entire new sector of people who want to store their child’s stem cells at birth. The number one objection to using our services is the pricing at time of birth. We believe this new program will solve that issue for many families.”
(OTC:CBAI.ob) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board:CBAI.ob), visit our website at www.corcell.com.
For investor information, visit www.cordblood-america.com.
*************************************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.StockHotTips.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold StockHotTips.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
pwrmcrwe060410
cbaicrwe060410
cbmxcrwe060410
*************************************************************
Sign-Up For Free Hot Stock Alerts At http://stockhottips.com/signup
*************************************************************
